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Summary
p53-dependent apoptosis is a major determinant of its tumor suppressor activity and can be triggered by hypoxia. No p53
target is known to be induced by p53 or to mediate p53-dependent apoptosis during hypoxia. We report that p53 can
directly upregulate expression of Bnip3L, a cell death inducer. During hypoxia, Bnip3L is highly induced in wild-type p53-
expressing cells, in part due to increased recruitment of p53 and CBP to Bnip3L. Apoptosis is reduced in hypoxia-exposed
cells with functional p53 following Bnip3L knockdown. In vivo, Bnip3L knockdown promotes tumorigenicity of wild-type
versus mutant p53-expressing tumors. Thus, Bnip3L, capable of attenuating tumorigenicity, mediates p53-dependent
apoptosis under hypoxia, which provides a novel understanding of p53 in tumor suppression.
Introduction apoptotic activity of p53 is essential for tumor suppression.
During tumor growth, hypoxia is a major stress that cells en-
counter (Achison and Hupp, 2003; Vaupel et al., 1991). To date,Solid tumors are poorly oxygenated as compared with normal
a number of p53 targets have been identified and proposed totissues and possess regions of hypoxia (Vaupel et al., 1991).
mediate p53-dependent cell death in response to genotoxicApoptosis induced by hypoxia is a mechanism for elimination
stresses (Fei et al., 2002; Nakano and Vousden, 2001; Oda etof stressed cells (Shimizu et al., 1996). In response to hypoxia,
al., 2000a, 2000b; Villunger et al., 2003; Jeffers et al., 2003).hypoxia-inducible factor 1 (HIF-1) activates genes involved in
However, none of them has been shown to mediate p53-depen-angiogenesis, anaerobicmetabolism, and iron homeostasis (Se-
dent cell death under hypoxia. In fact, p53 has been shown tomenza, 2000), which contribute to adaptive survival. HIF-1 also
be incapable of upregulating its known transcriptional targetsactivates proapoptotic members of the Bcl-2 family, including
during hypoxia, due to a failure to recruit coactivator proteinsBnip3L (Denko et al., 2003; Piret et al., 2002), which induces
such as CBP or p300 to their promoters (Koumenis et al., 2001).cell death, and plays an essential role in cardiac cell death
We report here that Bnip3L is a proapoptotic transcriptionalduring hypoxia (Kubasiak et al., 2002; Yussman et al., 2002).
target of p53. Its induction by p53 under hypoxia appears toUnder severe hypoxia, p53protein is stabilizedprobably through
occur through the recruitment of coactivator CBP to Bnip3L,
HIF-1-dependent (An et al., 1998; Carmeliet et al., 1998; Piret
leading to a greater magnitude of Bnip3L induction in wild-
et al., 2002; Hansson et al., 2002) and/or -independent mecha- type as compared to p53-deficient cells. Silencing of Bnip3L
nisms (Wenger et al., 1998; Pan et al., 2004). Wild-type p53- significantly blocks the apoptotic advantage in wild-type p53-
expressing tumor cells are targeted for apoptosis during hypoxia expressing cells under hypoxia. Bnip3L knockdown promotes
(Graeber et al., 1996). Thus, p53 is a key regulator of proliferation tumorigenicity in human tumor xenograft models if tumor cells
or survival during hypoxia associated with tumor progression contain wild-type but not mutant p53. In particular, nontumori-
(Schmaltz et al., 1998). genic U2OS osteosarcoma cells were converted into a tumori-
p53 is frequently mutated in human cancer and is consid- genic state following injection of nude mice with U2OS cells
ered a “guardian of the genome” in preventing cancer (Chan et harboring stable Bnip3L knockdown. Our results suggest that
al., 2000; Lane, 1992; Levine, 1997). Abundant evidence (Sy- Bnip3L can suppress tumor xenograft growth in vivo and is
monds et al., 1994; Attardi and Jacks, 1999; Aurelio et al., 2000; a mediator of p53-dependent apoptosis under hypoxia. The
Bardeesy et al., 1995; Eischen et al., 2001; Meijerink et al., 1998; regulation of Bnip3L by p53 provides a novel mechanism by
which p53 acts as a tumor suppressor in vivo.Schmitt et al., 2002; Soengas et al., 2001) indicates that the
S I G N I F I C A N C E
The p53 gene is important in tumor suppression during hypoxia, but none of its known proapoptotic targets is transactivated by p53
under hypoxic conditions. We show here that p53 can transactivate proapoptotic Bnip3L during hypoxia and that CBP and p53 are
recruited to Bnip3L in vivo. Although Bnip3L is a HIF target, its silencing only significantly protects cells in culture from apoptosis
induced by hypoxia if cells contain wild-type p53. Silencing Bnip3L promotes tumor growth in vivo through reduced sensitivity to
hypoxia and increased proliferation. This work provides insights into hypoxic death of tumors and possible strategies for therapeutic
restoration of tumor sensitivity during hypoxia.
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Figure 1. Bnip3L is a p53-regulated gene
A and B: Bnip3L induction at the mRNA level (A) or protein level (B) depends on wild-type p53 status following 5-FU and cisplatin (Cis) exposure of U2OS
cells. The arrows indicate the two human Bnip3L transcripts (3.9 and 1.6 kb). Ethidium staining shows the 18S rRNA in the lower panel as a loading control.
The quantification of Bnip3L induction by a phosphorimager is provided.
C: Bnip3L mRNA induction in MEFs carrying temperature-sensitive p53.
D and E: In vivo dependence of Bnip3L expression on wild-type p53 or  irradiation-induced DNA damage in mice by in situ hybridization analysis. Spl,
spleen; Ile, ileum; DC, descending colon; Duo, duodenum; Jej, jejunum.
Results expression was observed in wild-type p53-expressing U2OS
cells after treatmentwith 5-fluorouracil (5-FU) (5-fold) or cisplatin
Bnip3L is a p53-regulated gene (3-fold), as compared to untreated U2OS cells or treatment of
Among the known activities of p53, sequence-specific DNA U2OS cells carrying human papillomavirus E6 that targets p53
binding and transactivation explain the majority of its effects for degradation (Figure 1A). A similar pattern of Bnip3L protein
(El-Deiry, 1998). We hypothesized that the apoptotic effect of induction was observed in chemotherapy-treated U2OS-Neo
p53 under hypoxia may be mediated through transcriptional cells but not U2OS-E6 cells (Figure 1B). We further confirmed
control, which prompted us to analyze candidate apoptotic tar- the regulation of Bnip3L by p53 in VM10 murine embryonic
get(s) that might mediate p53-dependent cell death during hyp- fibroblasts carrying temperature-sensitive p53 (Sax et al., 2002)
oxia. Using a microarray screening approach (Sax et al., 2002),
and in p53/ versus p53/ mice. Bnip3L mRNA levels in-we found that Bnip3L is upregulated 2.8-fold by wild-type p53.
creased in VM10 cells whenwild-type p53 functionwas restoredBnip3L is a known apoptotic mediator (Piret et al., 2002) that
(32C), and a further increase occurred upon adriamycin expo-is ubiquitously expressed as 1.6 and 3.9 kb mRNA transcripts
sure (Figure 1C). Using in situ hybridization, we found that(Yasuda et al., 1999). To confirm that Bnip3L is a p53-regulated
Bnip3L expression (Figure 1D) increased in irradiated spleen,gene, we examined Bnip3L induction in human tumor cells with
ileum, and transverse colon of wild-type but not p53-deficientvarying p53 status before and after exposure to chemotherapeu-
tic agents (Figures 1A and 1B). A higher level of Bnip3L mRNA mice. We also noted a higher basal expression of Bnip3L in
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Figure 2. Bnip3L is a direct target of p53
A: The human Bnip3L gene, located on chr. 8, contains six exons (green rectangles) and five introns. Putative p53 binding sites (A, B, C, E, E, F, and F;
oval shapes) with 85% or greater homology to the p53 binding consensus sequence are shown along with their sequences (nucleotides in uppercase
indicate homology, whereas lowercase indicates a mismatch with the consensus). Fragments D and F contain two putative p53 binding sites each (E and
E or F1 and F2, respectively). The red color indicates the fragments (B, D, and E) that could mediate p53-dependent transactivation. The first nucleotide
is 8727 bp upstream of the first exon, based on the gene prediction method “BestRefseq” using accession number NT-023666. The relative locations for
exons and putative p53 sites are labeled.
B: P53 binds to human Bnip3L in vivo. U2OS cells were incubated with () or without () 2 g/ml 5-FU for 18 hr, and this was followed by a ChIP assay.
Anti-Rb antibody was used as a negative control. DR5, Puma, and Bax were used as positive controls.
C and D: p53 transactivates reporters containing Bnip3L fragments. Reporter constructs (labeled in the figure as A, B, C, D, E, or F) and the original pGL-3
plasmid vector (V) were mixed with a renilla luciferase-expressing plasmid at a ratio of 10:1 as a transfection efficiency control. Plasmids were transfected
into U2OS cells by Lipofectamine 2000 (Invitrogen). In D, reporter constructs with fragments B, D, or E or the pGL-3 vector (V) were transfected with pcDNA-
wtp53 in Saos-2 cells. The reporter construct containing fragment D was cotransfected with mtp53a (R248G) or mtp53b (R275H) in Saos-2 cells. Transfected
U2OS cells were plated in triplicate for 24 hr after transfection and treated with 2 g/ml 5-FU for 20 hr. The relative fold-luciferase activity was standardized
to the renilla luciferase activity. The DNA fragments B, D, and E increased reporter activity by 2-, 5-, and 3-fold in U2OS cells, and up to 6-, 10-, and 6-fold
high at 10 hr after transfection in Saos-2 cells, respectively, as compared to the basal reporter luciferase expression.
duodenumand jejunumofwild-type versus p53 null mice (Figure U2OS cells (Figure 2B). In contrast, no DNAwas recovered from
precipitates of untreated cells or cells immunoprecipitated with1E). Taken together, Bnip3L expression is induced by p53 fol-
lowing DNA damage in vitro and in vivo. an anti-RB control antibody. Thus, following 5-FU exposure,
p53 localizes to human Bnip3L in vivo. To confirm that these
p53 binding DNA segments can confer p53-dependent tran-Bnip3L is a direct target of p53
To gain insight into whether p53 might regulate Bnip3L directly, scriptional activity, the six DNA fragments containing the above
sites (Figure 2A) were cloned individually upstream of the mini-we searched the NCBI database and found that human Bnip3L
contains seven putative p53 DNA binding sites with 85% or mal SV40 promoter in a reporter plasmid. We found that the
D-reporter was activated 5-fold in 5-FU-treated U2OS cells (Fig-greater identity to the p53 consensus DNA binding sequence
(El-Deiry et al., 1992) (Figure 2A). To determine whether p53 ure 2C) and 10-fold in Saos-2 cells (Figure 2D) cotransfected
with a wild-type p53-expressing plasmid. The D-reporter wascan bind to candidate p53 sites in human Bnip3L, a chromatin
immunoprecipitation (ChIP) assay was performed using lysates not induced by either of two different mutant p53-expressing
plasmids (plasmid “a” contains mutant p53 with an R248G sub-from U2OS cells with or without 5-FU treatment. Precipitation
with an anti-p53 antibody of 200–300 bp DNA fragments corre- stitution, whereas plasmid “b” contains mutant p53 with an
R275H substitution). The B- and E-reporters were also inducedsponding to sites B, D, or E was observed in 5-FU-treated
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by p53 to similar levels (over 2-fold in U2OS cells and 6-fold in p53 targets in recruiting p53 protein to its genomic locus under
hypoxia.Saos-2 cells) as compared to the basal promoter vector (Figures
The work of Giaccia and colleagues indicated that p53 tar-2C and 2D). The expression levels of the transfected p53 pro-
gets induced by DNA damage are not upregulated during hyp-teins in Saos-2 cells and the original images of the luciferase
oxia, because p53 fails to recruit CBP or p300 to their DNAassays are provided in Supplemental Figure S1 at http://www.
binding sites (Koumenis et al., 2001). Here, we show that CBPcancercell.org/cgi/content/full/6/6/597/DC1/. These results
is efficiently recruited to the p53 DNA binding regions of Bnip3Lare consistent with the ChIP assay results (Figure 2B). Site A-
(regions B, D, and E), but not to Bax, Puma, or DR5 (Figure 4B).and C-reporters were weakly transactivated by p53 (Figure 2C),
This provides a mechanistic insight into the difference in thepossibly because they contain a spacer region between the
regulation of Bnip3L versus other known p53 targets underp53 DNA binding half-site decamers (Tokino et al., 1994). It
hypoxic conditions. Because HIF-1 is known to regulate Bnip3Lis possible that site E may have contributed to induction of
(Piret et al., 2002) and HIF-1 function relies on the coactivatorsluciferase activity in the D-reporter versus the E-reporter (Fig-
CBP and p300 (Arany et al., 1996), we hypothesized that HIF-1ures 2C and 2D). In summary, Bnip3L appears to be a target of
may recruit CBP to the Bnip3L locus regardless of p53. Wep53, which can be directly regulated by p53 through sequence-
found that five of six DNA fragments containing putative p53specific DNA binding and transcriptional activation.
DNA binding sites within Bnip3L were coimmunoprecipitated
with anti-CBP antibody under hypoxic conditions either in wild-Bnip3L, unlike other proapoptotic targets of p53,
type U2OS-Neo or p53-deficient U2OS-E6 cells (Figure 4B).remains inducible by p53 under hypoxia
However, not all of the fragments immunoprecipitated by theIn response to hypoxia, Bnip3L and its close family member
anti-CBP antibody were bound by p53 (Figures 2B and 4A).Bnip3 have been identified as apoptotic mediators (Denko et
Because CBPwas recruited toBnip3L in hypoxia-exposed p53-al., 2003; Sowter et al., 2001). Wild-type p53 accumulates in
deficient U2OS-E6 cells, the results argue that CBP recruitmenttumor cells under hypoxic conditions (Figure 3A) and can exert
is independent of p53 but may facilitate coactivation in cellsan apoptotic function (Graeber et al., 1996; Graeber et al., 1994).
with wild-type p53. Thus, p53 can enhance induction of Bnip3L,However, none of the known apoptotic targets of p53 appear
in concert with HIF-1 and/or other factors under hypoxic condi-to be induced by p53 or to mediate p53-dependent apoptosis
tions.under hypoxic conditions. Thus, we explored the possibility that
To further investigate the kinetics and magnitude of Bnip3L
Bnip3Lmay be regulated by p53 during hypoxia. We found that
induction in wild-type versus p53-deficient cells under hypoxic
Bnip3L mRNA is induced to significantly higher levels during
conditions, we performed a detailed time course to unravel the
hypoxia in wild-type p53-expressing U2OS-Neo, PA1-Neo, or relationships between Bnip3L mRNA, Bnip3L protein, and p53
parental U2OS cells as compared to the respective p53-defi- protein (Figure 4C). We found that Bnip3L mRNA induction oc-
cient U2OS-E6, PA1-E6, or Saos-2 cells (Figures 3B–3D). Simi- curs to higher levels in wild-type p53-expressing U2OS-Neo
larly, Bnip3L protein is elevated to much higher levels in wild- cells (16-fold) as compared to the observed 5-fold induction in
type p53-expressing cells as compared to p53-deficient control the U2OS-E6 cells (Figure 4C). The induction of Bnip3L mRNA
cells during hypoxia (Figures 3E and 3F). To investigate the and protein peaked at 24 hr after p53 stabilization and was
uniqueness of Bnip3L regulation by p53 under hypoxia, expres- detected by 18 hr in the hypoxia-exposed U2OS-Neo cells (Fig-
sion of theBnip3L-related Bnip3, or the other p53 targets Puma, ure 4C). It appears that increases in Bnip3L protein levels occur
DR5, Bax, or p21WAF1 was analyzed. Unlike Bnip3L, the induction to a much greater extent in wild-type p53-containing cells as
of hypoxia-inducibleBnip3was essentially identical among cells compared to the p53-deficient cells exposed to severe hypoxia
with or without functional p53 (Figure 3G). No transcriptional (Figure 4C). Thus, a clear difference in the magnitude of Bnip3L
induction of Puma, DR5, Bax, or p21 was observed under hyp- mRNA and protein induction depends on p53 status in hypoxia-
oxia (Figure 3G). In fact,Bax expression appeared to be reduced exposed cells. Bnip3L mRNA was induced 16-fold at 24 hr in
after hypoxia (Figure 3G), which is in agreement with recent U2OS-Neo cells but only 5-fold in the U2OS-E6 cells at 24 hr.
findings that Bax and Bid are repressed under hypoxia (Erler et Despite the 5-fold increase in Bnip3L mRNA expression by 24
al., 2004). These results indicate thatBnip3L, unlike other known hr after hypoxia, no increase in Bnip3L protein expression was
transcriptionally upregulated targets of p53, is upregulated by observed in the U2OS-E6 cells exposed to severe hypoxia for
p53 under hypoxia. Moreover, the regulation by p53 during 30 hr. This is in contrast to the 5-fold increase in Bnip3L protein
hypoxia is specific to Bnip3L and not to the closely related expression detected by 24 hr in hypoxia-exposed U2OS-Neo
Bnip3. cells (Figure 4C). Thus, one aspect of the importance of the
The contrast in induction patterns under hypoxia between p53-dependent regulation of Bnip3L involves the magnitude of
Bnip3L and other targets of p53 prompted us to determine Bnip3L mRNA and protein induction under conditions of hyp-
whether interactions of p53with its DNAbinding sites in chroma- oxia.
tin may vary among its target genes. ChIP assays revealed that
genomic regions of Bnip3L bound by p53 in response to 5-FU Bnip3L mediates p53-dependent
treatment (Figure 2B) were the same fragments bound by p53 apoptosis during hypoxia
under hypoxia (Figure 4A). In contrast, p53 did not localize to In response to hypoxia, p53 contributes to a higher apoptotic
the p53 binding regions of Bax, Puma, or DR5 under hypoxia activity in wild-type p53-containing cells (Schmaltz et al., 1998)
(Figure 4A), although p53 was observed to bind to these genes (Figures 5A and 5B). Bnip3L was highly induced in cells with
following exposure to genotoxic stresses (Figure 2B; Kaeser wild-type p53 (Figures 3 and 4C) as compared to the E6-
and Iggo, 2002). Thus, Bnip3L is directly bound by p53 under expressing cells under hypoxia. The kinetics of cell death in
hypoxia-exposed U2OS-Neo and U2OS-E6 cells (Figure 5B)hypoxia and appears to be unique among known proapoptotic
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Figure 3. Bnip3L is inducible by p53 under hypoxia
A: P53 protein level is elevated in response to severe hypoxia.
B–F: A higher Bnip3L mRNA (B–D) or protein (E and F) induction occurs during severe hypoxia in wild-type as compared to p53-deficient cells.
G: Wild-type p53 status does not predict expression levels of other proapoptotic targets, or the close family member of Bnip3L, Bnip3, under hypoxic
conditions. “” indicates normoxia in experiments; “” refers to 0.1% O2.
correlated well with the kinetics of Bnip3L mRNA and protein expressed (and thereforemay be sufficient to promote cell death
when induced by p53 under hypoxia).induction (Figure 4C). To further address the relevance of the
observed greater magnitude of induction of Bnip3L when cells We investigated the role of Bnip3L in p53-dependent cell
death under hypoxia through siRNA-mediated knockdown.contain wild-type p53, we generated Tet-inducible clones of
Bnip3L in a wild-type p53-deficient background (Figure 5C). siRNA oligonucleotides directed against Bnip3L in PA1-neo and
U2OS-Neo cells reduced Bnip3L mRNA by 80% (Figure 5D).Apoptosis was observed in the Tet-inducible clones of Bnip3L
following Bnip3L mRNA and protein induction in a manner inde- We found a 60% reduction in Bnip3L protein in the transfected
hypoxia-exposedU2OS-Neo cells (Figure 5E). Forced downreg-pendent of p53 regulation (Figure 5C). These results demon-
strate a dosage effect of Bnip3L mRNA and protein expression ulation of Bnip3L expression (Figures 5D and 5E) during hypoxia
was correlated with significant blockade of apoptotic death inwith regard to apoptosis and further support the idea thatBnip3L
induction is sufficient to induce apoptosis when conditionally wild-type p53-containing PA1-Neo and U2OS-Neo cells (Fig-
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Figure 4. Bnip3L remains as a direct target of p53 under hypoxia
A: P53 binds to the human Bnip3L locus but not to Bax, Puma, or DR5 during hypoxia in vivo. A ChIP assay was performed with anti-Rb antibody as a
negative control. For 22 hr, 0.1% O2 was used as the hypoxia condition.
B: CBP is recruited to the p53 binding region of Bnip3L but not to the p53 binding regions of Bax, Puma, or DR5. A ChIP assay was performed with anti-Rb
antibody as a negative control.
C: Kinetics and magnitude of induction of Bnip3L mRNA, Bnip3L protein, and p53 protein under severe hypoxia in U2OS cells. The quantitative information
for Bnip3L mRNA expression, analyzed using a phosphorimager, is provided below the blots.
ures 5F and 5G, upper panels). In contrast, the p53-deficient Knockdown of Bnip3L promotes human tumor
E6-expressing cell lines were not affected (PA1-E6; Figure 5F) xenograft growth in vivo
or became only slightly more resistant to cell death after Bnip3L Tumorsmust endure a certain level of hypoxia during their devel-
knockdown (U2OS-E6; Figure 5G). As additional evidence for opment (Hammond et al., 2002; Vaupel et al., 1991). Wild-type
these effects, we tested different Bnip3L RNAi sequences (Sup- p53-expressing tumor cells, which possess a higher apoptotic
plemental Figure S2 at http://www.cancercell.org/cgi/content/ activity, are naturally eliminated during tumor formation (Graeber
full/6/6/597/DC1/). Bnip3L knockdown protected PA1-Neo and et al., 1996). The high apoptotic activity of wild-type p53-
U2OS-Neo cells from the apoptotic effects of severe hypoxia expressing cells under hypoxia correlates well with the high
(Supplemental Figure S2). The results in Figure 5 and Supple- frequency of p53 mutations in human tumors, which provide a
mental Figure S2 suggest that Bnip3L contributes to apoptotic selective growth advantage under hypoxic stress during tumor
death in wild-type p53-expressing cells exposed to hypoxia. evolution and progression. Because Bnip3L is a proapoptotic
The induction of Bnip3L by hypoxia in E6-expressing cells ap- target of p53 functioning under hypoxic conditions, a role in
pears to have little effect in inducing cell death as noted by
suppressing tumor formation may provide a mechanism by
the lack of substantial change in percent of cells undergoing
which p53 mediates tumor suppression, particularly under hyp-apoptosis following Bnip3L knockdown. The kinetics of the ob-
oxic conditions. Thus, in order to elucidate the importance ofserved death and lack of significant effect following Bnip3L
Bnip3L in tumor formation, we generated stable cell lines U-11knockdown correlate well with the observation that Bnip3L pro-
and U-17 (derived fromU2OS) that constitutively express siRNAtein expression in E6-expressing cells was not detectably ele-
directed against human Bnip3L, or pooled U2OS cells infectedvated under the conditions studied here (Figure 4C). These re-
with Bnip3L RNAi-expressing retrovirus (U2OS p3LKD cells)sults support the conclusion that Bnip3L appears to mediate in
(Supplemental Figure S3A at http://www.cancercell.org/cgi/part p53-dependent apoptosis under hypoxia. These studies
content/full/6/6/597/DC1/). At 10 days after injection of 10 mil-suggested apossibility thatwe further tested, that loss ofBnip3L
lion cells (U-11, U-17, U2OS p3LKD, or selected control parentalregulation in part through p53 dysfunctionmay afford a selective
growth advantage to tumors under hypoxic conditions. cells U2OS-s; control and Bnip3L knockdown injections on op-
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Figure 5. Bnip3L is a mediator of p53-dependent cell death under hypoxia
A and B: Higher apoptotic activity is observed in wild-type p53-expressing PA1-Neo and U2OS-Neo cells as compared to PA1-E6 and U2OS-E6 cells exposed
to severe hypoxia.
C: Induction of exogenous Bnip3L mRNA and protein expression promotes apoptosis in mutant p53-expressing SW480 tumor cells following use of the Tet-on
inducible system to restore regulated expression of Bnip3L. The level of Bnip3L mRNA progressively increased according to the dose of doxycycline. Bnip3L
protein was clearly increased at the highest dose of doxycycline (see 54 hr time point). The percentage of cell death correlated with the increased level
of Bnip3L protein. No increase in cell death was observed in parental SW480 cells treated with 1 g/ml doxycycline for 54 hr (data not shown). The
quantitative information for Bnip3L mRNA expression is provided below the blots.
D and E: Both levels of Bnip3L mRNA (D) and protein (E) were analyzed to determine the efficiency of RNAi by real-time quantitative RT-PCR (D) or Western
blotting under hypoxia (E). A similar result to that in Figure 5E was noted in Western blotting the RNAi-transfected PA1 cells (data not shown).
F and G: Knockdown of Bnip3L diminishes the apoptotic death in both PA1-Neo and U2OS-Neo cells. “3Li” refers to Bnip3L RNAi-transfected cells.
posite flanks as indicated in Supplemental Figure S3B), the U- PA1 xenograft (PA1-s) over time, and a slight growth advantage
was also observed in the mutant p53-expressing SW480 xeno-11, U-17, and pooled U2OS p3LKD xenografted cells formed
tumors. In contrast, the U2OS-s xenograft disappeared by 5 grafts with Bnip3L knockdown (Supplemental Figure S4). These
data suggest that Bnip3L suppresses tumor growth as a tumordays after injection, consistent with prior reports that U2OS
cells do not form tumors in nude mice (American Type Culture suppressor, particularly in tumors that contain wild-type p53.
We speculate that the ultimate reduction of bioluminescence inCorporation; Anderson et al., 2000). In subsequent experiments,
a constitutively expressing firefly luciferase gene cloned in a the Bnip3L-silenced U2OS derivatives (data not shown beyond
21 days) may reflect the action of other p53 targets and/orretrovirus vector was introduced into the U2OS-s, U-11, U-17,
and p3LKD cells to monitor the dynamic course of tumor forma- other death inducing protein(s), which may contribute to tumor
suppression. Moreover, host immunity resulting from NK celltion in nudemice. Bioluminescence intensities (Figure 6) of firefly
luciferase-expressing U-11, U-17, or p3LKD and U2OS-s, were activity and/or other factors may contribute to the elimination
of U2OS-derivative xenografts and the eventual suppression ofroughly equal, with perhaps more signal from the parental
U2OS-s injection sites at the beginning of the experiment (day the Bnip3L-silenced tumors.
0). On subsequent days, the bioluminescence emitted from the
U2OS-s cells decreased as compared to the U-11, U-17, or Bnip3L is a mediator of p53-dependent radiosensitivity
Wild-type p53 plays a critical role in radiosensitivity (Fei et al.,p3LKD xenografts, and gradually the control bioluminescence
from the U2OS-s xenografts disappeared (compare days 0, 3, 2002; Fei and El-Deiry, 2003). Tumors harboring mutations in
p53 generally carry a poor prognosis following radiotherapy, asand 6 in Figure 6). In contrast, the bioluminescence emitted
by the U-11, U-17, or p3LKD xenografts initially increased in has been observed, for example, in breast cancer (Marchetti et
al., 2003). However, the efficacy of ionizing radiation directlyintensity and persisted through day 21 (Figure 6) and subse-
quently decreased (data not shown). A higher intensity of biolu- relies on adequate oxygen tensions (Weinmann et al., 2003).
To probe a potential role of Bnip3L in p53-dependent radiosen-minescence was also observed in Bnip3L knockdown PA1 xe-
nografts (Supplemental Figure S3C) as compared to the control sitivity, mice were irradiated with 5 Gy on day 4 after injection
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Figure 6. Knockdown of Bnip3L promotes tumorigenicity
U-11, U-17, pooled U2OS 3L knockdown (p3LKD; Bnip3L silencing was mediated through retrovirus infection of RNAi-expressing cDNA), or U2OS-s cells were
infected with firefly luciferase-expressing retroviruses. Ten million cells of each were injected into mice. On day 0, xenografts of U2OS-s/U-11 (upper), U2OS-
s/U-17 (middle), and U2OSs/p3LKD (bottom) emitted similar levels of bioluminescence, or there was a slightly higher emission from the U2OS-s xenografts.
Bioluminescence was imaged over time and quantified. The bioluminescence from U2OS-s xenografts disappeared by day 6, whereas U-11, U-17, and
p3LKD xenografts continued to emit light detectable up to day 21 shown here. A typical mouse image (the same mouse is shown over the time course)
is presented from a total of four mice for U-11/U-17 xenografts or from a total of eight mice for p3LKD xenografts. Quantification with error bars of the
photon counts per unit time per cm2 from the wild-type (U2OS-s) as compared to the Bnip3L-silenced tumor xenografts appears to the right.
of 10 million U2OS-s versus either U-11 or p3LKD cells (Figure (Figure 7D and Supplemental Figure S5D at http://www.
cancercell.org/cgi/content/full/6/6/597/DC1/). Immunostaining7A and Supplemental Figure S5A at http://www.cancercell.org/
cgi/content/full/6/6/597/DC1/). On day 4, the U2OS-s xeno- for the Ki67 antigen confirmed the proliferative advantage in the
U-11 and p3LKD tumors inwhichBnip3Lwas silenced (comparegrafts were still alive and were excised at 6 hr after irradiation and
compared with the nonirradiated controls (Figure 7A and Supple- Figure 7D and Supplemental Figure S5D), and staining for active
caspase 3 confirmed a lower level of apoptosis in U-11 versusmental Figure S5). Active caspase-3 appeared to be significantly
increased in irradiated U2OS-s xenografts as compared to the U2OS-s and p3LKD versus U2OS-s (Figure 7D and Supplemen-
tal Figure S5D). However, examination of either Glut1 expressionnonirradiated U2OS-s and either the irradiated or untreated U-11
or p3LKD xenografts (Figures 7B and 7C; Supplemental Figures (Figure 7D) or pimonidazole adducts (Supplemental Figure S5D)
showed comparable staining between U2OS-s, U-11, or U2OSS5B and S5C). There was more active caspase-3 in irradiated
U-11 or p3LKD versus unirradiated U-11/p3LKD xenografts, re- p3LKD tumors, suggesting similar degrees of hypoxia. These
results suggest that silencing of Bnip3L does not reduce thespectively, consistent with the hypothesis that Bnip3L may be
involved in but is likely not the only mediator of apoptosis following hypoxic gene induction response leading to increased Glut1
expression; rather, despite the hypoxia, there is reduced apo-irradiation. Nonetheless, silencing of Bnip3L appears to reduce
apoptotic activity initiated in irradiated wild-type p53-containing ptosis and increased proliferation in the U-11 or p3LKD versus
U2OS-s tumors. One interpretation is that silencing of Bnip3Lxenografts, suggesting an important role for Bnip3L among the
apoptotic targets of p53. results in reduced sensitivity to hypoxia and increased cell sur-
vival that is permissive for tumor proliferation and the observed
growth advantage of U-11 or p3LKD tumors under hypoxia.Decreased sensitivity to hypoxia in vivo contributes
to tumor growth following Bnip3L
silencing in U2OS xenografts Discussion
We further examined the U2OS-s control, U-11, and pooled
U2OS (p3LKD) tumors with Bnip3L silencing to gain insights A high frequency of p53 mutations is associated with a growth
advantage in developing tumors (Vogelstein et al., 2000). Nu-into whether the growth advantage and greater proliferation in
U-11 or p3LKD may be due to reduced sensitivity to hypoxia. merous studies have documented (Symonds et al., 1994; Attardi
and Jacks, 1999; Aurelio et al., 2000; Bardeesy et al., 1995;U2OS-s, U-11, or p3LKD xenografts were excised from tumor-
bearing mice on day 4, prior to regression of the U2OS-s tumors Eischen et al., 2001; Meijerink et al., 1998; Schmitt et al., 2002;
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Figure 7. Knockdown of Bnip3L is accompanied by reduced apoptosis in irradiated or unirradiated xenografts, and the reduced sensitivity to hypoxia-
mediated cell death is accompanied by increased proliferation of tumors
A–C: Two mice were injected with 10 million cells of U2OS-s or U-11 cells. On day 4 (images in A), mice were either untreated or treated with 5 Gy ionizing
radiation, and the xenografts were excised 6 hr later. The image shown was obtained from one of the two mice (the same mouse) at the two different
time points shown. The active caspase-3 signal (brown color in cytoplasm) (B) was highest in the irradiated (IR) U2OS-s xenograft, moderate in the
nonirradiated (IR) U2OS-s xenograft, low in the IR U-11 xenograft, and lowest in the unirradiated U-11 xenograft. The relative amount of active caspase-3
expression is shown (C) by using NIH ImageJ software.
D: Day 4 xenografts were harvested, and the nonirradiated U2OS-s or U-11 xenografts revealed similar levels of Glut1. In Bnip3L-silenced xenografts, active
caspase-3 levels were lower, whereas Ki67 expression was higher as compared to the control xenograft.
Soengas et al., 2001) that the apoptotic effect of p53 plays a P53 induces Bnip3L under hypoxia
Bnip3L, unlike its family member Bnip3, not only responds tocritical role in tumor suppression. To date, several proapoptotic
targets of p53 have been suggested to mediate p53-dependent HIF-1 (Sowter et al., 2001; Bruick, 2000) but also responds to
wild-type p53 (Figures 1–3). Other known proapoptotic targetsapoptosis following exposure to genotoxic stresses. However,
none of the known p53-activated proapoptotic genes has been of p53 are either uninduced (Koumenis et al., 2001), repressed
(Figure 3G; Erler et al., 2004), or induced without a preferenceshown to mediate p53-dependent apoptosis in response to
hypoxia, as it occurs during tumor development and progres- to p53 status in hypoxic cells (Kim et al., 2004). To date, Bnip3L
is the only apoptotic target of p53 identified that appears to besion. Here, we demonstrate that Bnip3L is a recognized target
of p53 and is a strong candidate mediator of p53-dependent upregulated by wild-type p53 in response to hypoxia. Here, we
show that p53 localizes to the p53 DNA binding sites of Bnip3Lapoptosis during hypoxia. Importantly,Bnip3L appears to inhibit
tumorigenicity such that silencing of Bnip3L allows conversion but not to Bax, Puma, or DR5 during hypoxia (Figure 4A), al-
though these targets can be induced and p53 localizes to theirof nontumorigenic U2OS-s cells to tumorigenic xenografts. Si-
lencing Bnip3L reduces sensitivity to apoptosis under hypoxic genomic loci following DNA damage. A failure of p53 to trans-
activate its known targets under hypoxia has been previouslyconditions, thereby permitting a higher degree of proliferation
(Figure 7D and Supplemental Figure S6A). These studies sug- reported and was attributed to a lack of recruitment of CBP or
p300 to their genomic loci (Koumenis et al., 2001).We confirmedgest that loss of Bnip3L regulation by p53 under hypoxia may
be a pivotal event in tumor development, which contributes to the lack of induction of Bax, Puma, or DR5 during hypoxic
exposure of wild-type p53-expressing human tumor cell linesdecreased apoptosis, and cells with lowered apoptotic potential
(Graeber et al., 1996) grow into tumors. Taken together, the (Figure 3G). We confirmed that CBP is not recruited to the
p53 DNA binding regions of Bax, Puma, or DR5 (Figure 4B)work shown here provides a mechanism regarding how p53
induces apoptosis and suppresses tumors under hypoxic condi- consistent with the Koumenis et al. (2001) model. However,
CBP was efficiently localized to the p53 DNA binding regionstions. Moreover, this work provides a mechanistic insight into
the selection pressure that occurs under hypoxia and an apo- of Bnip3L (Figure 4B). Two regions that bound CBP, including
p53 DNA binding site-containing fragments A and C, were notptotic mediator that needs to be suppressed to permit tumor
growth. shown to be bound by p53 (Figures 2B and 4A), which suggests
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of its location near the first coding exon of Bnip3L (Figure 2A),
its ability to bind p53 (Figure 2B) including under hypoxia (Figure
4A), and its potential to mediate p53-dependent transactivation
of promoter-reporter plasmids (Figures 2C and 2D). Moreover,
a candidate HIF site (Supplemental Figure S6B at http://www.
cancercell.org/cgi/content/full/6/6/597/DC1/) is locatedwithin 850
base pairs of the p53 site B. Thus, it is possible that CBP is
recruited to the genomic region of site B through HIF, and then
p53 can be recruited to the region through its DNA binding
response element. We note that the mouse Bnip3L locus con-
tains candidate p53 binding sites, with 80% homology to the
consensus sequence, both upstream of the first coding exon
and downstream of the last coding exon (Supplemental Figure
S6C). We also note that there are two candidate p53 binding
sites with 75% homology to the p53 consensus in intron 1 of
mouse Bnip3L (Supplemental Figure S6C) and that there is a
75% homology site in intron 1 of human Bnip3L (data not
shown). Thus, regulation of Bnip3L by p53 appears to be con-
Figure 8. Model of Bnip3L regulation by p53 under hypoxia served between human andmouse cells, as evidenced by struc-
A: Under normoxia, p53 recruits coactivators (Co-a) CBP or p300 to its con- tural similarity between the two loci (Figure 2A andSupplemental
sensus binding sequence (CBS) and transactivates its target genes in re- Figure S6C) and evidence for p53-dependent Bnip3L induction
sponse to DNA damage. During hypoxia, p53 fails (B) to recruit coactivators in both species (Figures 1–3). In the future, more detailed studies
to its binding sequence and does not transactivate its known proapoptotic
will examine the contribution of specific p53 sites to Bnip3Ltargets or p21. Bnip3L, through HIF-1 (C), recruits coactivator CBP close to
regulation under various conditions including DNA damage andp53 binding regions under hypoxia. p53 protein interacts with CBP while
interacting with its binding sites. A cooperative interaction involving HIF-1, hypoxia, with detailed analysis of the spatial and temporal inter-
CBP, andp53 is proposed to lead to higher levels of Bnip3L in cells containing actions between HIF-1, CBP, and p53 proteins at the genomic
wild-type p53. In such cells, Bnip3L appears to be a major mediator of
regulatory region of Bnip3L. To date, an analysis documentingapoptosis when the cells are exposed to severe hypoxia.
the importance of any specific genomic DNA response element
for p53 has not been performed for any gene, including those
that contain multiple p53 sites. Such studies on the mecha-
nism(s) by which p53, CBP, and HIF coordinately regulatethat other cis elements within Bnip3Lmay play an essential role
Bnip3L may provide a greater understanding of Bnip3L regula-in the recruitment of CBP to Bnip3L under hypoxia. We propose
tion during p53-dependent tumor suppression under hypoxiaa model (Figure 8) aiming to explain how p53 may regulate
and may help to find ways to maintain or restore apoptoticBnip3L under hypoxia. Under hypoxic conditions, p53 fails to
target gene expression and prevent tumor progression.interact with CBP (Koumenis et al., 2001) and interacts with
its p53 DNA binding sites weakly and transiently (Figure 8B).
Bnip3L is an apoptotic mediatorHowever, p53 may interact with CBP and bind firmly to putative
of p53 under hypoxic conditionsp53 DNA binding sites when the local level of CBP is stimulated
We have shown a clear difference in the magnitude of Bnip3Lby HIF-1, which primes the putative p53 DNA binding sites in
mRNA and protein induction depending on p53 status in hyp-the vicinity of HIF-1 response elements (HRE). We speculate
oxia-exposed cells (Figure 4C). p53 protein stabilization oc-that CBP promotes p53 recruitment by altering chromatin struc-
curred before the induction of Bnip3L mRNA and protein, andture to allow access to DNA binding sites for p53 or by physical
a much greater extent of induction of Bnip3L was found in wild-proximity to allow interaction between CBP and p53 (Figure
type p53-containing cells as compared to p53-deficient cells8C), and this will not occur in p53-deficient cells, although CBP
following exposure to hypoxia. Thus, p53 appears to play amay be present (Figure 4B). In our studies, p53 protein is absent
critical role in the magnitude of Bnip3L induction under hypoxia.in E6-expressing cells under hypoxia, although HIF-1 protein is
We believe that the magnitude of Bnip3L induction in wild-present (Supplemental Figure S6A at http://www.cancercell.
type p53-expressing hypoxic cells is a major determinant oforg/cgi/content/full/6/6/597/DC1/). Thus, in cells lacking p53,
subsequent cell death. To further explore the possible impor-our model predicts a failure to optimally induce Bnip3L to suffi-
tance of the greater magnitude of induction of Bnip3L in wild-cient levels, thereby leading to resistance to the apoptotic effect
type p53-containing cells exposed to hypoxia, we establishedof severe hypoxia.
Tet-inducible clones of Bnip3L in mutant p53-expressingWe note that the genomic locus of Bnip3L contains p53
SW480 cells. This design was intended to (1) uncouple p53DNA binding sites upstream of the first coding exon and down-
regulation from the level of Bnip3L induction and (2) determinestream of the last coding exon (Figure 2A). It is not uncommon
whether Bnip3L induction to high levels (not normally achievedfor p53-regulated genes to contain multiple p53 response ele-
in the absence of wild-type p53) would be sufficient to inducements or to have sites located within downstream introns. It is
apoptosis in p53-deficient cells. The Tet-inducible Bnip3Lnot clear if sites downstream of coding exons are significantly
SW480 cells demonstrated that there is a dosage effect ofdifferent in function from sites located within introns in terms
Bnip3L mRNA and protein expression with regard to the ob-of transactivation by p53. Nonetheless, the genomic region con-
served apoptosis (Figure 5C). ThisBnip3L-dependent apoptosistaining site B is a good candidate mediator of the observed
p53-dependent Bnip3L transactivation under hypoxia because in a p53-deficient background required high levels of Bnip3L
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mRNA and protein, and correlated well with what we described the p53 tumor suppressor functions in vivo in inhibiting tumor
development.regarding Bnip3L regulation under hypoxia in wild-type versus
p53-deficient U2OS cells (Figure 4C). Cells deficient in p53 func-
tion showed only modest increases inBnip3LmRNA expression Altered Bnip3L regulation by p53 in cancer
that we believe may not result in efficient cell death induction Deficient Bnip3L upregulation may occur in several ways in
under hypoxia (Figure 4C). Moreover, the studies using Tet- tumors. These include the loss of functional p53 through p53
inducible Bnip3L in p53-deficient SW480 cells confirm that mutation, or loss of Bnip3L function. Some mutations of Bnip3L
Bnip3L is sufficient to induce apoptosis when conditionally ex- have been reported in breast cancer and ovarian cancer; its
pressed and therefore may be sufficient when induced by p53 expression is low or absent in both lung cancer cell lines and
under hypoxia. This is important because p53 may induce other human lung cancers (Lai et al., 2003; Sun et al., 2004). This
targets that may be involved in cell death under hypoxia, but is consistent with the present demonstration that silencing of
induction of Bnip3L is sufficient once a certain level of induction Bnip3L promotes tumorigenicity (Figure 6 and Supplemental
is reached. Figures S3 and S4 at http://www.cancercell.org/cgi/content/
To further support our conclusion that p53-dependent regu- full/6/6/597/DC1/). In addition, there is a possibility that Bnip3L
lation of Bnip3L under hypoxia is relevant to the observed apo- regulation by p53 could be impaired during tumor formation
ptosis and tumor suppression, we investigated the effects of even in some tumors that retain wild-type p53, possibly through
Bnip3L silencing in p53-deficient cells. The p53-deficient cells changes in selectivity of target gene activation that promote
were already more resistant to hypoxia-induced apoptosis (Fig- tumor growth. For example, we observed no Bnip3L upregula-
ures 5A and 5B), and the magnitude of Bnip3L mRNA and tion by p53 in HCT116 or H460 tumor cell lines following expo-
protein induction by hypoxia was low (Figure 4C). Silencing of sure to DNA damaging agents or hypoxia (data not shown). A
Bnip3L in p53-deficient U2OS-E6 cells only slightly reduced the recent report demonstrated, among other changes, downregu-
observed apoptosis following exposure to hypoxia (Figure 5G) lation of Bnip3L in HCT116 cells selected for resistance to 5-FU
as compared to U2OS-Neo cells, where a dramatic protection (De Angelis et al., 2004). Another study reported hypermethyla-
was observed (Figure 5G). Taken together with the results of tion of Bnip3 in pancreatic cancer (Okami et al., 2004). Thus, a
the Tet-inducibleBnip3L experiments (Figure 5C), these findings number of genetic or epigenetic changes, which may occur
reinforce two conclusions: (1) p53-deficient human tumor cells during tumor progression, may lead to the loss ofBnip3L regula-
die inefficiently when exposed to severe hypoxia, despite the tion by p53 when both are present, thereby contributing to
fact that Bnip3L and other hypoxia-inducible targets are in- decreased sensitivity to hypoxia and tumor progression.
duced, and (2) blockade of Bnip3L has much more significant Bnip3L and Bnip3 are potent apoptotic mediators during
effects on hypoxia-induced cell death in wild-type p53-express- hypoxia (Kubasiak et al., 2002; Piret et al., 2002; Yussman et
ing cells because of its greater magnitude of induction. We al., 2002); however, Bnip3 is not upregulated by p53. Interest-
believe the greater magnitude of Bnip3L induction represents ingly, we found that the kinetics of Bnip3 mRNA and protein
the contribution of p53 to hypoxia-induced cell death and further induction were slower than those of Bnip3L mRNA and protein
conclude that hypoxic death is inefficient in p53-deficient cells, induction in hypoxia-exposed SW480 cells (Supplemental
possibly because sufficient levels of Bnip3L are not achieved Figure S4C at http://www.cancercell.org/cgi/content/full/6/6/
(Figure 4C). When such levels are artificially created in cells 597/DC1/), and in vivo knockdown of Bnip3 in the SW480 cells
lacking wild-type p53, cell death is observed (Figure 5C). We had no apparent effect on xenograft growth (Supplemental Fig-
conclude that the greater sensitivity to hypoxia in wild-type p53- ures S4A and S4B). Taken together, without upregulation by
containing cells results from Bnip3L regulation by p53, but we p53, Bnip3L or Bnip3 may play a role in hypoxia-triggered cell
cannot rule out other mediators of p53, direct effects of p53, death with a suggestion that Bnip3L may be induced earlier
and/or other factors that may also contribute to the cell death and contribute slightly more to the cell death. However, these
triggered by hypoxia. effects are weak in terms of their tumor suppressive potential
Bnip3L appears to play a crucial role in tumor suppression in cells lacking wild-type p53, and such p53-deficient human
as documented by our observations that silencing of Bnip3L cells appear to have little difficulty in surviving and forming
lowers sensitivity to cell death induced by hypoxia (Figure 7D tumors in vivo, regardless of the silencing of either Bnip3 or
and Supplemental Figure S5D at http://www.cancercell.org/cgi/ Bnip3L. Bnip3L appears to play a crucial role in tumor suppres-
content/full/6/6/597/DC1/) in vivo. Moreover, Bnip3L knock- sion that is compromised when p53 is mutated or Bnip3L is
down converts nontumorigenic U2OS cells into tumorigenic xe- silenced, and its induction provides a mechanism by which p53
nografts. This was demonstrated by two approaches: (1) stable functions in vivo in inhibiting tumor growth. In tumor progres-
clonal cells and (2) retrovirus-infected pooled cells to eliminate sion, cells with lower expression of Bnip3L have a lower apo-
potential artifacts due to selection during cloning procedures ptotic potential, and this may facilitate their growth and expan-
(Figure 6). These results are consistent with the concept that a sion despite hypoxia (Figures 6 and Supplemental Figures S3
lower apoptotic potential promotes tumor growth (Graeber et and S4). In tumor therapy, a lower expression of Bnip3L is
al., 1996), and this may be compromised when p53 is mutated. expected to contribute to radioresistance (Figure 7B and Sup-
In our studies, the blockade of tumor suppression due toBnip3L plemental Figure S5B). We suggest that Bnip3L regulation by
silencing occurred in U2OS xenografts, despite the fact that p53 may contribute to hypoxia-induced cell death and tumor
these cells contain wild-type p53 and maintain a modest apo- suppression. The restoration ofBnip3L induction in cancer treat-
ptotic response to ionizing irradiation (Figure 7B and Supple- ment therefore offers a strategy for promoting increased sensi-
mental Figure 5B). We propose that p53-dependent upregula- tivity to hypoxia and increased apoptosis in response to therapy
of hypoxic tumors.tion of Bnip3L during hypoxia provides a mechanism by which
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nase gene using a transcriptional targeting approach. Cancer Gene Ther. 7,Experimental procedures
845–852.
Reporter plasmids, transfection, and reporter imaging assays Arany, Z., Huang, L.E., Eckner, R., Bhattacharya, S., Jiang, C., Goldberg,
Six genomic DNA fragments containing sites A, B, C, D, E, and F (in Figure M.A., Bunn, H.F., and Livingston, D.M. (1996). An essential role for p300/
2A) were cloned into the pGL3 promoter-reporter (Promega). Transfection CBP in the cellular response to hypoxia. Proc. Natl. Acad. Sci. USA 93,
was performed using Lipofectamine 2000 (Invitrogen). The bioluminescent 12969–12973.
images were obtained using a Xenogen IVIS as previously described (Wang
Attardi, L.D., and Jacks, T. (1999). The role of p53 in tumour suppression:and El-Deiry, 2003, 2004).
lessons from mouse models. Cell. Mol. Life Sci. 55, 48–63.
Bnip3L siRNA oligonucleotide transfection Aurelio, O.N., Kong, X.T., Gupta, S., and Stanbridge, E.J. (2000). p53mutants
siRNA oligonucleotides directed against human Bnip3L included 5-AA-CAG have selective dominant-negative effects on apoptosis but not growth arrest
UUCCUGGGUGGAGCUA-3 for Supplemental Figure S3 (http://www. in human cancer cell lines. Mol. Cell. Biol. 20, 770–778.
cancercell.org/cgi/content/full/6/6/597/DC1/) and 5-AA-CACGUACCAUCC
Bahnson, A.B., Dunigan, J.T., Baysal, B.E., Mohney, T., Atchison, R.W.,UCAUCCU-3 for Figure 4, and scrambled oligonucleotides were purchased
Nimgaonkar, M.T., Ball, E.D., and Barranger, J.A. (1995). Centrifugal en-from Dharmacon Research (Lafayette, CO). The transfection was performed
hancement of retroviral mediated gene transfer. J. Virol. Methods 54,
as suggested by Dharmacon. 131–143.
Bardeesy, N., Beckwith, J.B., and Pelletier, J. (1995). Clonal expansion andXenograft formation
attenuated apoptosis in Wilms’ tumors are associated with p53 gene muta-Nude mice (4–6 weeks old) from Charles River laboratory were injected with
tions. Cancer Res. 55, 215–219.300 l Matrigel (Invitrogen) flurry (prepared at a 1:1 ratio with 1 PBS)
containing 10million cells with or without constitutively expressed luciferase. Bruick, R.K. (2000). Expression of the gene encoding the proapoptotic Nip3
The luciferase activity was measured by intraperitoneal injection of 50 mg/ protein is induced by hypoxia. Proc. Natl. Acad. Sci. USA 97, 9082–9087.
mouse D-luciferin into anesthetized mice, followed by detection of live im-
Brummelkamp, T.R., Bernards, R., and Agami, R. (2002). A system for stableages using the Xenogen IVIS as described (Wang and El-Deiry, 2003, 2004).
expression of short interfering RNAs in mammalian cells. Science 296,
550–553.Establishment of stable siRNA-expressing cell lines
and luciferase-expressing retrovirus Bunnell, B.A., Muul, L.M., Donahue, R.E., Blaese, R.M., and Morgan, R.A.
Bnip3LRNAi-expressing cDNA (see 64 nt sequences provided in the Supple- (1995). High-efficiency retroviral-mediated gene transfer into human and
mental Data at http://www.cancercell.org/cgi/content/full/6/6/597/DC1/) nonhuman primate peripheral blood lymphocytes. Proc. Natl. Acad. Sci.
was cloned into pSuper or Super-retro plasmid, and firefly luciferase cDNA USA 92, 7739–7743.
was cloned into pBabe-puro plasmid. The retroviruses made from Phoenix
Burns, T.F., and El-Deiry, W.S. (2001). Identification of inhibitors of TRAIL-cells were spinoculated into cells as described (Bunnell et al., 1995; Bahnson
induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480
et al., 1995; Burns and El-Deiry, 2001). The cell line selection was performed using a genetic approach. J. Biol. Chem. 276, 37879–37886.
as described previously (Brummelkamp et al., 2002).
Carmeliet, P., Dor, Y., Herbert, J.M., Fukumura, D., Brusselmans, K., Dewer-
chin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998).Inducible Bnip3L expression using the Tet-on system
Role of HIF-1 in hypoxia-mediated apoptosis, cell proliferation and tumourThese procedures were performed according to the protocol provided by
angiogenesis. Nature 394, 485–490.the manufacturer of the Tet-on system (Clontech). The Bnip3L cDNA was
subcloned into the pRevTRE vector at the BamH1 and the HindIII sites. Chan, T.A., Hwang, P.M., Hermeking, H., Kinzler, K.W., and Vogelstein, B.
(2000). Cooperative effects of genes controlling the G(2)/M checkpoint.
Supplemental data Genes Dev. 14, 1584–1588.
A more detailed description of the Experimental Procedures is provided
De Angelis, P.M., Fjell, B., Kravik, K.L., Huag, T., Tunheim, S.H., Reichelt,in the Supplemental Data at http://www.cancercell.org/cgi/content/full/6/6/
W., Beigi, M., Clausen, O.P., Galteland, E., and Stokke, T. (2004). Molecular597/DC1/.
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